ITGAM and neoplasm: We found that 70.73 ± 1.30% of the CD11b+Gr-1− cells were F4/80− and MHCII− in tumors, which was the same as the e-MDSCs subset in mice, compared with only 15.10 ± 3.10% of CD11b+Gr-1− cells being F4/80− and MHCII− in the spleens of tumor-bearing mice (Figures 3C,D).